Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
monoclonal antibody andantineoplastic that binds to EGFR, under investigation for the treatment ofcancer .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word necitumumab.
Examples
-
But Erbitux sales have slowed after the discovery that it wasn't effective in people with a certain genetic profile, and Lilly and partner Bristol-Myers Squibb Co. recently halted a late-stage trial of experimental cancer drug necitumumab because of safety concerns.
Sanofi Needs to Avoid Pitfalls of Pharma-Biotech Deals Peter Loftus 2011
-
The companies said they will continue to study necitumumab, which has no approved use, in a separate late-stage study that combines it with Lilly's Gemzar and cisplatin to treat another form of lung cancer.
unknown title 2011
-
Bristol-Myers stopped one of two late-stage studies of its biologic drug for non-small cell lung cancer, necitumumab, in February after signs of increased risk of dangerous blood clots.
-
INDIANAPOLIS AP -- Drugmakers Eli Lilly and Co. and Bristol-Myers Squibb Co. said Wednesday they stopped enrolling patients in one of two late-stage studies of the potential cancer treatment necitumumab due to concerns about blood clots.
unknown title 2011
-
Lilly maintains exclusive rights to necitumumab in all other markets.
-
The company restructured the collaboration agreement executed by Bristol-Myers Squibb and ImClone in 2001 to allow for the co-development and co-commercialization of the late-stage oncology molecule necitumumab (IMC-11F8), which is currently in Phase III clinical testing for non-small cell lung cancer.
THE MEDICAL NEWS 2010
-
As restructured, both companies will share in the cost of developing and potentially commercializing necitumumab in the U.S.,
-
As John mentioned earlier in January November Lilly and Bristol-Myers Squibb restructured our existing collaboration agreement to allow for the co-development and co-commercialization of necitumumab, or IMC11F8 which is currently in phase III clinical trials for non-small scale lung cancer.
-
Under the restructured agreement, both companies will share in the cost of developing and potentially commercializing necitumumab in the U.S.,
THE MEDICAL NEWS 2010
-
As restructured, both companies will share in the cost of developing and potentially commercializing necitumumab in the U.S.,
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.